982 results on '"Vermorken, Jan B."'
Search Results
2. Treatment Intensification in Locoregionally Advanced Head and Neck Squamous Cell Carcinoma: What Are the Options and for Whom?
3. Cetuximab : its unique place in head and neck cancer treatment
4. Season of radiotherapy and outcomes of head & neck cancer patients in the MACH-NC & MARCH meta-analyses
5. Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in Older Patients: Are New Agents Bringing New Hope?
6. Gynecologic Cancer
7. Steering decision making by terminology: oligometastatic versus argometastatic
8. ESO-ESSO-ESTRO Multidisciplinary Course in Oncology for Medical Students: 4 Years of Experience (2016–2019)
9. Where and when to Use Induction Chemotherapy in Head and Neck Squamous Cell Cancer
10. High-Dose Three-Weekly or Low-Dose Weekly Cisplatin during Radiation, What to Prefer?
11. The outcome of patients with serous papillary peritoneal cancer, fallopian tube cancer, and epithelial ovarian cancer by treatment eras: 27 years data from the SEER registry
12. Academia Oncology: a forum for interdisciplinary cancer research
13. Treatment of Elderly Patients with Head and Neck Cancer
14. Management of recurrent and metastatic oral cavity cancer: Raising the bar a step higher
15. Season of radiotherapy and outcomes of head & neck cancer patients in the MACH-NC & MARCH meta-analyses
16. Treatment in the Elderly
17. Immunotherapeutic Approaches
18. Patient and Treatment Factors in Concurrent Chemoradiotherapy
19. Multidisciplinary Decision Making and Head and Neck Tumor Boards
20. The 'Make Sense Campaign': An Initiative of the European Head and Neck Society
21. Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial
22. Prognostic and predictive factors in recurrent and/or metastatic head and neck squamous cell carcinoma: A review of the literature
23. Editorial: Head and neck cancer in the elderly
24. Human Papillomavirus (HPV): A Criterion for Therapeutic Decision in Squamous Cell Carcinoma of the Head and Neck?
25. Cell Based Therapy: Modified Cancer Cells
26. Altered fractionation radiotherapy combined with concurrent low-dose or high-dose cisplatin in head and neck cancer: A systematic review of literature and meta-analysis
27. Prognostic value of c-MET in head and neck cancer: A systematic review and meta-analysis of aggregate data
28. Critical Issues in Head and Neck Oncology
29. Unraveling the Mechanism of Radiosensitization by Gemcitabine: The Role of TP53
30. Supplementary Table 2 from Clinical Effects of Adjuvant Active Specific Immunotherapy Differ between Patients with Microsatellite-Stable and Microsatellite-Instable Colon Cancer
31. Supplementary Figure 2 from Clinical Effects of Adjuvant Active Specific Immunotherapy Differ between Patients with Microsatellite-Stable and Microsatellite-Instable Colon Cancer
32. Supplementary Table 1 from Clinical Effects of Adjuvant Active Specific Immunotherapy Differ between Patients with Microsatellite-Stable and Microsatellite-Instable Colon Cancer
33. Supplementary Figure 1 from Clinical Effects of Adjuvant Active Specific Immunotherapy Differ between Patients with Microsatellite-Stable and Microsatellite-Instable Colon Cancer
34. Supplementary Figure 3 from Clinical Effects of Adjuvant Active Specific Immunotherapy Differ between Patients with Microsatellite-Stable and Microsatellite-Instable Colon Cancer
35. Supplementary Figure 4 from Clinical Effects of Adjuvant Active Specific Immunotherapy Differ between Patients with Microsatellite-Stable and Microsatellite-Instable Colon Cancer
36. Editorial: Insights in head and neck cancer: 2021
37. Novel Immunotherapeutic Approaches to Treating HPV-Related Head and Neck Cancer
38. HIPEC in advanced epithelial ovarian cancer: why is there controversy?
39. Systemic Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
40. Toxicities of systemic agents in squamous cell carcinoma of the head and neck (SCCHN); A new perspective in the era of immunotherapy
41. Reporting Quality of Randomized, Controlled Trials Evaluating Combined Chemoradiotherapy in Nasopharyngeal Carcinoma
42. Estimating the Prevalence of a True Oligometastatic Disease
43. Clinical recommendations for defining platinum unsuitable head and neck cancer patient populations on chemoradiotherapy: A literature review
44. Systemic treatment in elderly head and neck cancer patients: recommendations for clinical practice
45. Sepsis in head and neck cancer patients treated with chemotherapy and radiation: Literature review and consensus
46. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial
47. Barriers to clinical trial recruitment in head and neck cancer
48. Prevention of head and neck squamous cell carcinoma: Removing the “chemo” from “chemoprevention”
49. Gynecologic Cancer
50. Overcoming cetuximab resistance in HNSCC: The role of AURKB and DUSP proteins
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.